Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Comparison of Norepinehrine Versus Phenylepherine Infusion for Prevention of Post-spinal Hypotension

22. juni 2026 opdateret af: Ahmed Abdelhameed Fares, Sohag University

Comparison of Norepinephrine Versus Phenylephrine Infusion for Prevention of Hypotension Due to Subarachnoid Block in Elderly Patients Undergoing Orthopedic Hip Surgery:A Prospective Randomized Trial

This prospective randomized double-blinded clinical trial aims to compare the efficacy and hemodynamic effects of prophylactic norepinephrine infusion versus phenylephrine infusion for prevention of spinal anesthesia-induced hypotension in elderly patients undergoing elective orthopedic hip surgery under subarachnoid block. Sixty-two patients aged 60 years or older will be randomly assigned into two equal groups to receive either norepinephrine infusion (8 µg/min) or phenylephrine infusion (100 µg/min) immediately after spinal anesthesia. The primary outcome is the mean heart rate during vasopressor infusion, while secondary outcomes include incidence of hypotension, severe hypotension, bradycardia, reactive hypertension, intraoperative fluid requirements, blood loss, transfusion requirements, and postoperative nausea and vomiting. Hemodynamic parameters will be monitored throughout surgery to evaluate the safety and effectiveness of both vasopressor strategies.

Studieoversigt

Detaljeret beskrivelse

Spinal anesthesia-induced hypotension is a common and clinically significant complication in elderly patients undergoing orthopedic hip surgery. Age-related physiological changes, impaired autonomic responses, and reduced cardiovascular reserve increase susceptibility to hypotension after subarachnoid block, which may result in organ hypoperfusion, myocardial ischemia, nausea, vomiting, and increased perioperative morbidity.

Phenylephrine is traditionally used for prevention and treatment of spinal anesthesia-induced hypotension because of its potent alpha-adrenergic vasoconstrictive effect. However, its use may be associated with reflex bradycardia and reduction in cardiac output. Norepinephrine, which possesses both alpha-adrenergic and mild beta-adrenergic activity, may provide better maintenance of heart rate and cardiac output while effectively preserving blood pressure.

This prospective randomized double-blinded clinical trial will be conducted at the Department of Anesthesia, Intensive Care and Pain Management, Sohag University Hospitals, after approval from the Institutional Ethics Committee. Elderly patients aged 60 years or older, classified as ASA physical status I-III and scheduled for elective orthopedic hip surgery under spinal anesthesia, will be enrolled after obtaining written informed consent.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

62

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Fawzy Abbas Badawy, Professor

Studiesteder

      • Sohag, Egypten
        • Rekruttering
        • Sohag university hospital
        • Kontakt:
          • Mohamed N Hamdoun, Professor

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  1. Age 60 years or older.
  2. ASA physical status I-III.
  3. Scheduled for elective hip surgery under subarachnoid block.
  4. Willing to provide written informed consent.

Exclusion Criteria:

  1. Patient refusal.
  2. Contraindications to subarachnoid block.
  3. Severe cardiac disease.
  4. Uncontrolled hypertension.
  5. Allergy to study drugs.
  6. Emergency surgery.
  7. Monoamine oxidase inhibitor use.
  8. Cognitive impairment preventing informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Norepinehrine group
• NE group: norepinephrine infusion at 8 µg/min. Infusion will continue for 45 minutes after spinal anesthesia.
norepinephrine infusion at 8 µg/min. Infusion will continue for 45 minutes after spinal anesthesia.
Eksperimentel: Phenylepherine group
PhE group: phenylephrine infusion at 100 µg/min Infusion will continue for 45 minutes after spinal anesthesia.
phenylephrine infusion at 100 µg/min. Infusion will continue for 45 minutes after spinal anesthesia.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean intaroperative heart rate (beats /minute) during vasopressor infusion measured by continous electrocardiogrammonitoring
Tidsramme: From the start of subarachnoid block until the end of surgery .
Heart rate will be continously monitored using standar electrocardiogram monitoring. to compare the effect of norepinephrine versus phenylephrine infusion on hemodynamics.
From the start of subarachnoid block until the end of surgery .

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of spinal anesthesia-induced hypotension
Tidsramme: From the administration of spinal anesthesia until the end of the procedure.
Defined as a decrease in mean arterial pressure (MAP) to <80% of baseline measurd by non-invasive blood pressure monitoring .
From the administration of spinal anesthesia until the end of the procedure.
Incidence of bradycardia
Tidsramme: Throughout the intraoperative period
Defined as heart rate ≤ 50 beats/min.
Throughout the intraoperative period
Mean arterial pressure (MAP) trends measured using non-invasive blood pressure monitoring
Tidsramme: Every 5 minutes from the start of spinal anesthesia until the end of surgery.
Monitoring the stability of blood pressure during vasopressor infusion
Every 5 minutes from the start of spinal anesthesia until the end of surgery.
Incidence of reactive hypertension measured by non-invasive blood pressure monitoring
Tidsramme: From the start of vasopressor infusion until the end of surgery.
Defined as mean arterial pressure (MAP) > 125% of baseline.
From the start of vasopressor infusion until the end of surgery.
Total intraoperative intavenous fluid
Tidsramme: At the end of the surgical procedure.
Total volume of intravenous fluids administered in milliliters
At the end of the surgical procedure.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. maj 2026

Primær færdiggørelse (Anslået)

14. marts 2027

Studieafslutning (Anslået)

14. marts 2027

Datoer for studieregistrering

Først indsendt

22. maj 2026

Først indsendt, der opfyldte QC-kriterier

22. juni 2026

Først opslået (Faktiske)

23. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Norepinephrine

3
Abonner